Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine effect on insulin secretion
NCT02910076Phase 2Unknown
- Sponsor
- Hadassah Medical Organization
- Start
- Oct 2016
- Primary completion
- Aug 2018
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of hydroxychloroquine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Hadassah Medical Organization. Primary endpoint: glucose level at 3 hours. Status: unknown.
02
Drugs
hydroxychloroquine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02910076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02910076.